#2-68E. Optimizing Prognosis in MDA5+ DM-ILD: The Case for Front-line Baricitinib (Arthritis Res Ther, 2025)

How should clinicians optimize therapeutic strategies for anti-MDA5 antibody positive dermatomyositis-associated interstitial lung disease (MDA5+ DM-ILD), a condition notorious for its high mortality rate and challenging treatment response? This retrospective cohort study evaluated the efficacy and safety of the Janus kinase (JAK) inhibitor baricitinib in 39 patients with MDA5+ DM-ILD. Treatment with baricitinib led to significant clinical improvements in cutaneous manifestations (Gottron's sign, heliotrope rash), pulmonary function (FVC), and the normalization of key inflammatory markers like serum ferritin and LDH. Crucially, the baricitinib group demonstrated improved six-month survival compared to controls (87.2% vs. 70%, P=0.047), with the most significant advantage observed when the drug was utilized as front-line therapy (84.6% vs. 52.9%, P=0.046). This strongly suggests that early, potent intervention may alter the disease trajectory. We must, however, acknowledge the study's limitations, particularly its retrospective, single-center cohort design, which introduces inherent selection bias and limits the generalizability of findings. This evidence provides essential guidance for clinical decision-making, strongly supporting the early introduction of baricitinib for patients with this aggressive disease to maximize clinical impact and survival.

Citation: Zhu S, et al. Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease. Arthritis Research & Therapy. 2025. DOI: 10.1186/s13075-025-03675-9

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.